IOBT Heidi Hunter buys $21K worth of shares
Jun 03, 2025, 4:38 AM
0.00%
What does IOBT do
IO Biotech develops immune-modulating cancer therapies using its Twin technology platform, targeting tumor-induced immunosuppression. Its lead candidate, IO102-IO103, addresses key proteins IDO and PD-L1.
Heidi Hunter bought 15,000 shares of IOBT on 30 May at $1.39 per share, worth a total of $21K. They now own 15,000 IOBT shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.